Project Grant R56HL174545
Award Date
9/26/24
Completion Date
9/30/24
Dollars Obligated
$733K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
The federal Project Grant award for $121,773.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award is supporting research at the University of Arizona focused on understanding the role of the cytosolic kinase SGK1 in driving pathological cardiac hypertrophy, a precursor to heart failure. The project aims to determine the effects of depleting SGK1 on cardiac myocyte hypertrophy, as well as the impact of...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This $699,133 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports a multi-year research project to investigate the epigenetic and transcriptomic regulation of heart failure with preserved ejection fraction (HFPEF) across multiple organ systems. The research team at the University of California, Los Angeles (UCLA) will measure changes in gene expression, chromatin accessibility,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), aims to investigate the role of cardiomyocyte glutamine synthesis in cardiac physiology and heart failure. The $772,808 award under the Cardiovascular Diseases Research program (CFDA 93.837) will fund a 4-year research project at Temple University to: 1) examine if targeting cardiomyocyte glutamine synthesis can reduce the development of heart failure in...
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research program with three independent projects related to genetic and molecular mechanisms of heart disease. The first project aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the regulation of...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
The federal Project Grant award of $122,268, awarded on February 3, 2025 by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the University of New Mexico Health Sciences Center (UNM HSC) on the role of mitochondrial acid-sensing ion channel 1 in pulmonary hypertension. The project aims to advance scientific understanding of the mechanisms underlying cardiovascular diseases through this innovative research...
This $777,258 federal Project Grant, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to improve the understanding of heart failure in patients with hypertrophic cardiomyopathy (HCM). The primary focus is to use advanced cardiac MRI techniques, including exercise cardiac MRI, to better characterize the underlying pathophysiology and guide the use of novel cardiac myosin inhibitor pharmacotherapies or established...